You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 8,440,854


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,440,854 protect, and when does it expire?

Patent 8,440,854 protects SKYCLARYS and is included in one NDA.

This patent has sixty patent family members in twenty-nine countries.

Summary for Patent: 8,440,854
Title:Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Abstract:This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula:
Inventor(s):Anderson Eric, Jiang Xin, Visnick Melean
Assignee:Reata Pharmaceuticals, Inc.
Application Number:US13356455
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

United States Patent 8,440,854: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 8,440,854, assigned to Reata Pharmaceuticals Holdings LLC, is a significant patent in the field of pharmaceuticals, particularly focusing on antioxidant inflammation modulators. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background and Patent History

The patent in question, U.S. Patent 8,440,854, is a continuation of U.S. patent application Ser. No. 12/426,778, filed on April 20, 2009. This application claims the benefit of priority to U.S. Provisional Applications Ser. No. 61/046,342 and 61/111,269, filed on April 18, 2008, and November 4, 2008, respectively[2].

Scope of the Patent

The patent pertains to antioxidant inflammation modulators, specifically oleanolic acid derivatives. These compounds are designed to treat various inflammatory and oxidative stress-related conditions. The scope of the patent encompasses the chemical structures, methods of synthesis, and therapeutic applications of these compounds.

Claims Analysis

The claims of a patent are its most critical components, as they define the scope of protection granted to the inventor. Here are some key aspects of the claims in U.S. Patent 8,440,854:

Independent Claims

The patent includes independent claims that describe the core inventions. These claims typically outline the novel and non-obvious aspects of the invention, such as specific chemical structures, formulations, and methods of use.

Dependent Claims

Dependent claims build upon the independent claims, providing additional details and limitations. These claims may include specific dosages, administration routes, or combinations with other therapeutic agents.

Claim Construction

The construction of claims is crucial for determining the patent's scope. This involves interpreting the language of the claims to understand what is covered and what is not. In the context of U.S. Patent 8,440,854, claim construction would involve analyzing the chemical structures, synthesis methods, and therapeutic uses to ensure clarity and specificity[1].

Patentability Requirements

For a patent to be granted, it must meet several patentability requirements:

Eligible Subject Matter Requirement

The invention must fall within the categories of "process, machine, manufacture, or composition of matter, or . . . improvement thereof." The Supreme Court has held that laws of nature, natural phenomena, and abstract ideas are not patentable[1].

Novelty Requirement

The invention must be new and not obvious to one skilled in the art. This means that the invention must not have been previously disclosed or used publicly before the patent application was filed.

Nonobviousness Requirement

The invention must be non-obvious, meaning it must represent a significant improvement over existing technology.

Utility Requirement

The invention must have a practical application and be capable of being used for a specific purpose.

Requirements for Specification and Claims

The patent application must include a detailed specification and claims that clearly define the invention. The specification must enable one skilled in the art to make and use the invention, and the claims must be definite and particular[1].

Patent Landscape Analysis

To understand the broader patent landscape, several tools and strategies can be employed:

Patent Analytics

Patent analytics involves analyzing the claims and scope of patents to identify gaps or opportunities in intellectual property protection. Tools like Claim Coverage Matrix and Claim Charts can help in categorizing patents by claims and scope concepts, making it easier to review patent coverage and identify areas for improvement[3].

Global Dossier

The Global Dossier service provided by the USPTO allows users to access file histories of related applications from participating IP Offices. This can help in understanding the global patent family and identifying potential overlaps or conflicts[4].

Public Search Facilities

The USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs) offer resources for searching and analyzing patent documentation. These facilities can be invaluable for conducting thorough patent landscape analyses[4].

Case Law and Judicial Precedents

Judicial decisions can significantly impact the interpretation and enforcement of patent claims. For instance, the case of Astellas Pharma Inc. v. Sandoz Inc. highlights the importance of proper claim construction and the role of courts in adjudicating patent validity. In this case, the district court's decision to invalidate certain claims was vacated due to procedural errors, emphasizing the need for careful consideration of patent eligibility and validity[5].

Current Debates and Reforms

The patent landscape is continually evolving, with ongoing debates and proposed reforms. The Patent Trial and Appeal Board (PTAB), established by the Leahy-Smith America Invents Act (AIA), plays a crucial role in administrative challenges to patent validity. Current debates include issues of standing, burdens of proof, discretionary institution of inter partes reviews (IPRs), claim construction, and the role of the USPTO Director in reviewing PTAB decisions[1].

Key Takeaways

  • Scope and Claims: U.S. Patent 8,440,854 covers antioxidant inflammation modulators, specifically oleanolic acid derivatives, with detailed claims defining the chemical structures, synthesis methods, and therapeutic applications.
  • Patentability Requirements: The patent must meet requirements of eligible subject matter, novelty, nonobviousness, utility, and proper specification and claims.
  • Patent Landscape Analysis: Tools like patent analytics, Global Dossier, and public search facilities are essential for understanding the broader patent landscape.
  • Judicial Precedents: Judicial decisions significantly impact patent interpretation and enforcement, highlighting the importance of proper claim construction and procedural adherence.
  • Current Debates and Reforms: Ongoing debates and reforms, particularly around PTAB and IPRs, continue to shape the patent landscape.

FAQs

What is the main subject matter of U.S. Patent 8,440,854?

The main subject matter is antioxidant inflammation modulators, specifically oleanolic acid derivatives.

How do patent analytics tools help in managing patent portfolios?

Patent analytics tools help by categorizing patents by claims and scope concepts, identifying gaps or opportunities in intellectual property protection, and facilitating the review of patent coverage with technical experts.

What is the role of the Patent Trial and Appeal Board (PTAB) in patent adjudication?

PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, including inter partes reviews (IPRs) and post-grant reviews (PGRs).

How do judicial decisions impact patent claims?

Judicial decisions can validate or invalidate patent claims based on their interpretation of patentability requirements and procedural adherence, significantly impacting the enforcement and scope of patent protection.

What resources are available for conducting patent landscape analyses?

Resources include the USPTO Public Search Facility, Patent and Trademark Resource Centers (PTRCs), Global Dossier, and Common Citation Document (CCD) services.

Cited Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," May 28, 2024.
  2. Gale, "Patent Issued for Antioxidant inflammation modulators: oleanolic acid derivatives," accessed December 22, 2024.
  3. Schwegman, Lundberg & Woessner, P.A., "Patent Analytics," accessed December 22, 2024.
  4. United States Patent and Trademark Office, "Search for patents," accessed December 22, 2024.
  5. United States Court of Appeals for the Federal Circuit, "Astellas Pharma Inc. v. Sandoz Inc.," September 18, 2024.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,440,854

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Reata Pharms SKYCLARYS omaveloxolone CAPSULE;ORAL 216718-001 Feb 28, 2023 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,440,854

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 074895 ⤷  Subscribe
Australia 2009237579 ⤷  Subscribe
Australia 2009312820 ⤷  Subscribe
Brazil PI0911457 ⤷  Subscribe
Brazil PI0916116 ⤷  Subscribe
Canada 2721838 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.